FDA approves painkiller said to thwart addiction
Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years

What happened
The Food and Drug Administration Thursday approved a new class of pain pill that is not addictive like opioids. Suzetrigine, being sold as Journavx by Vertex Pharmaceuticals, is the first new pharmaceutical treatment for pain to win FDA approval in more than 20 years.
Who said what
Opioids work by binding to receptors in the brain that receive pain signals from nerves around the body, but "those chemical interactions also give rise to opioids' addictive effects," The Associated Press said. But while prescription opioids have helped fuel an epidemic of addiction and overdoses, suzetrigine "works differently," intercepting pain signals before they reach the brain.
In two clinical trials submitted by Vertex, suzetrigine was more effective than a placebo at treating short-term pain in people recovering from stomach and foot surgery, and on par with a combined acetaminophen-hydrocodone pill, like Vicodin.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
What next?
Journavx was approved to treat acute pain in adults. But at a list price of $15.50 a pill, it "faces some hurdles in winning over physicians, hospitals and insurance companies," The Washington Post said. The new painkiller is promising because "there are a number of people who, once they have an opioid, want an opioid constantly," University of Washington pain expert Dr. John Loeser said to The New York Times. But acetaminophen-opioid pills are "dirt cheap."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Rafi Schwartz has worked as a politics writer at The Week since 2022, where he covers elections, Congress and the White House. He was previously a contributing writer with Mic focusing largely on politics, a senior writer with Splinter News, a staff writer for Fusion's news lab, and the managing editor of Heeb Magazine, a Jewish life and culture publication. Rafi's work has appeared in Rolling Stone, GOOD and The Forward, among others.
-
5 meritorious cartoons about the war on DEI
Cartoons Artists take on self-evident truths, recent history, and more
By The Week US Published
-
Bucatini alla zozzona recipe
The Week Recommends Classic Roman dish is 'slurpy, fun and absolutely heavenly'
By The Week UK Published
-
The UK 'spy cops' scandal, explained
The Explainer Undercover police targeting activist groups conducted intrusive surveillance, with some even embarking on relationships under assumed identities
By The Week UK Published
-
How Trump's executive orders are threatening scientific research
In the spotlight Agencies are purging important health information
By Devika Rao, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
America is leaving WHO. What does that mean for public health?
Today's Big Question Trump orders the withdrawal
By Joel Mathis, The Week US Published
-
Why is the FDA slow to ban food additives?
Today's big question A legal loophole lets things slide
By Devika Rao, The Week US Published
-
Is this the end of cigarettes?
Today's Big Question An FDA rule targets nicotine addiction
By Joel Mathis, The Week US Published
-
The UK's first legal drug consumption room
The Explainer 'Potentially transformative moment in UK drugs policy' as The Thistle opens in Glasgow
By The Week UK Published